Harnessing one of the most essential pathways in the innate immune system to generate effective therapies.
Rigontec is a leading company in the immune-oncology field developing compounds interacting with RIH-I receptor. The company was acquired August 2017 by MSD for up to EUR 463 million.
- CEO Dr. Christian Schetter
- Industry Biotech
- History M&A